Tetrahydroquinoline derivatives
View Patent ↗The present invention relates to tetrahydroquinoline derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 is formyl, (1-6C)alkylcarbonyl or (1-6C)alkylsulfonyl; R 2 and R 3 are H or (1-4C)alkyl; R 4 is phenyl; R 5 is (1-4C)alkyl; Y—X is (CO)—O, (SO) 2 —O, NHC(O)—O, NHC(S)—O, OC(O)—O, bond-O, C(O)—NH, S(O) 2 —NH, NHC(O)—NH, NHC(S)—NH, OC(O)—NH, bond-NH, NH—C(O), O—C(O), NH—S(O) 2 , or O—S(O) 2 or Y—X is a bond; R 6 is H, trifluormethyl, (1-6C)alkyl, 1- or 2-adamantyl(1-4C)alkyl, (2-6C)alkenyl, (3-9C)heteroaryl, (3-6C)cycloalkyl, (2-6C)heterocycloalkyl, (1-4C)alkylthio(1-4C)alkyl, (6-10C)aryl(1-4C)alkyl, (3-9C)heteroaryl(1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl(1-4C)alkyl, R 8 ,R 9 -aminocarbonyl(1-4C)alkyl, R 8 ,R 9 -amino(1-4C)alkyl, R 8 -oxycarbonyl(1-4C)alkyl, R 8 -oxy(1-4C)alkyl, R 8 -carbonyl(1-4C)alkyl or (6-10C)aryl; R 7 is H, (1-4C)alkyl, (1-4C)alkoxy, halogen, trifluoromethyl, cyano, nitro hydroxyl; and R 8 and/or R 9 is H, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (6-10C)aryl, (3-9C)heteroaryl, (6-10C)aryl(1-4C)alkyl, (3-9C)heteroaryl(1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl(1-4C)alkyl, (1-4C)(di)alkylamino(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylthio(1-4C)alkyl, (1-4C)alkylcarbonylamino(1-4C)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl, (1-4C)alkoxycarbonylamino(1-4C)alkyl, (3-6C)cycloalkyl, (2-6C)heterocycloylkyl, or R 8 and R 9 may be joined in a (2-6C)heterocycloalkyl ring. The present invention also relates to pharmaceutical compositions comprising said derivatives and the use of these derivatives to control fertility.
1. A pharmaceutical composition, comprising an effective amount of a compound according to Formula I,
or a pharmaceutically acceptable salt thereof, wherein
R 1 is (1-6C)alkylcarbonyl;
R 2 and R 3 are (1-4C)alkyl;
R 4 is phenyl, optionally substituted with one or more substituents selected from the group hydroxy, halogen, (1-4C)alkyl, and (1-4C)alkoxy;
R 5 is (1-4C)alkyl;
Y—X is C(O)—O, C(O)—NH or OC(O)—NH;
R 6 is (1-6C)alkyl, 1- or 2-adamantyl(1-4C)alkyl, heteroaryl selected from imidazolyl, thiadiazolyl, pyridyl, (benz)thienyl, (benzo)furyl, quinolyl, tetrahydroquinolyl, quinoxalyl, indolyl, thienyl and furyl, phenyl(1-4C)alkyl, (1-4C)alkylheteroaryl, wherein the heteroaryl is selected from imidazolyl, thiadiazolyl, pyridyl, (benz)thienyl, (benzo)furyl, quinolyl, tetrahydroquinolyl, quinoxalyl, indolyl, thienyl and furyl, heterocycloalkyl(1-4C)alkyl, wherein the heterocycloalkyl is selected from piperidine, morpholine and pyrrolidine, R 8 ,R 9 -aminocarbonyl(1-4C)alkyl, R 8 ,R 9 -amino(1-4C)alkyl, R 8 -oxycarbonyl(1-4C)alkyl, R 8 -oxy(1-4C)alkyl or phenyl, wherein phenyl is optionally substituted with nitro, trifluoromethyl, chlorophenyl, pyridyl, morpholinocarbonyloxy, isoxazolecarbonyloxy, oxazolidinoneoxycarbonyl, (1-4C)alkoxycarbonyl(1-4C)alkylcarbonyloxy, (1-4C)alkylsulfonyloxy, dimethylisoxazolesulfonyloxy, and (di)phenylamino, one or more of halogens, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)(di)alkylamino, phenyl, or (1-4C)(di)alkylcarbamoyl;
R 7 is H, (1-4C)alkyl, or (1-4C)alkoxy;
R 8 is (1-4C)alkyl, phenyl(1-4C)alkyl, heteroaryl(1-4C)alkyl, wherein the heteroaryl is selected from imidazolyl, thiadiazolyl, pyridyl, (benz)thienyl, (benzo)furyl, quinolyl, tetrahydroquinolyl, quinoxalyl, indolyl, thienyl and furyl, (3-6C)cycloalkyl(1-4C)alkyl, heterocycloalkyl(1-4C)alkyl, wherein the heterocycloalkyl is selected from piperidine, morpholine and pyrrolidine, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl, t-butylcarbamoyl, benzyl optionally substituted with (1-4C)alkoxy or one or more halogens, or R 8 together with R 9 may form a heterocycloalkyl selected from azetidine, pyrrolidine, piperidine, piperazine, thiomorpholine and morpholine, wherein the heterocycloalkyl ring is optionally substituted with phenyl, and
R 9 is H, or (1-4C)alkyl,
and a pharmaceutically acceptable auxiliary.
2. The pharmaceutical composition according to claim 1 , wherein in the tetrahydroquinoline compound of formula I, Y—X is C(O)—NH.
3. The pharmaceutical composition according to claim 2 , wherein in the tetrahydroquinoline compound of formula I, R 6 is heteroaryl selected from imidazolyl, thiadiazolyl, pyridyl, (benz)thienyl, (benzo)furyl, quinolyl, tetrahydroquinolyl, quinoxalyl, indolyl, thienyl and furyl, phenyl(1-4C)alkyl, (1-4C)alkylheteroaryl, wherein the heteroaryl is selected from imidazolyl, thiadiazolyl, pyridyl, (benz)thienyl, (benzo)furyl, quinolyl, tetrahydroquinolyl, quinoxalyl, indolyl, thienyl and furyl, or phenyl optionally substituted with nitro, trifluoromethyl, chlorophenyl, pyridyl, morpholinocarbonyloxy, isoxazolecarbonyloxy, oxazolidinoneoxycarbonyl, (1-4C)alkoxycarbonyl(1-4C)alkylcarbonyloxy, (1-4C)alkylsulfonyloxy, (1-4C)alkylsulfonyloxy, dimethylisoxazolesulfonyloxy, or (di)phenylamino, one or more of halogens, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)(di)alkylamino, phenyl, or (1-4C)(di)alkylcarbamoyl.